Alnylam vs. Pfizer: RNAi Patent Battle Closes After 1,114 Days

Introduction

One of the most closely watched RNA interference (RNAi) patent disputes in recent pharmaceutical litigation history has reached its conclusion. Alnylam Pharmaceuticals, Inc. v. Pfizer, Inc. et al. (Case No. 1:22-cv-00924) closed on July 30, 2025, after 1,114 days of litigation before the Delaware District Court under Chief Judge Colm F. Connolly. The case was resolved not through trial verdict but through consolidation — closed per entry of final judgment in a lead case.

At the center of this RNAi patent infringement action stood U.S. Patent No. US11382979B2, covering foundational lipid nanoparticle (LNP) and RNA delivery technology, and three commercially significant drug products: Alnylam’s own GIVLAARI® and OXLUMO®, alongside Pfizer/BioNTech’s LEQVIO® — a cholesterol-lowering therapy representing billions in commercial revenue. For patent attorneys, IP professionals, and R&D teams navigating the increasingly competitive RNAi therapeutics space, this case carries significant strategic weight.

Case Overview

The Parties

The Patent at Issue

The asserted patent, US11382979B2 (application number US17/644907), covers RNAi-related technology central to the formulation and delivery of RNA-based therapeutics. This patent sits within a broader family of LNP delivery patents that Alnylam has consistently positioned as foundational to any commercial RNAi or mRNA product.

The Accused Products were:

• • GIVLAARI® (givosiran) — Alnylam’s own approved RNAi therapy for acute hepatic porphyria
• • OXLUMO® (lumasiran) — Alnylam’s RNAi therapy for primary hyperoxaluria type 1
• • LEQVIO® (inclisiran) — A cholesterol-lowering RNAi therapy co-developed with Novartis/The Medicines Company

Litigation Timeline & Procedural History

Timeline

Filed: July 12, 2022

Closed: July 30, 2025

Duration: 1,114 days (~3 years)

The case was filed in the District of Delaware — the preeminent venue for pharmaceutical patent litigation and the jurisdiction of choice for cases involving major biopharma entities. Delaware’s experienced patent judiciary, predictable procedural timelines, and established case law on Hatch-Waxman and biologics IP disputes made it the strategic filing choice.

Chief Judge Colm F. Connolly presided over the matter. Judge Connolly is well known in IP circles for his rigorous management of complex pharmaceutical patent cases and his standing orders requiring transparency regarding litigation funding — a notable procedural hallmark of his courtroom.

The case closed as consolidated — terminated per entry of final judgment in a lead case. This procedural resolution indicates the dispute was absorbed into a related or parallel action, a common outcome when multiple overlapping cases involve the same patents, parties, or technological issues. Specific interim milestones such as claim construction orders, summary judgment rulings, or discovery disputes were not disclosed in available records.

A duration of 1,114 days reflects the complexity typical of multi-defendant, multi-product RNAi patent litigation, though consolidation ultimately streamlined the final resolution.

The Verdict & Legal Analysis

Outcome

The case closed on July 30, 2025, through consolidation — terminated per entry of final judgment in the lead case. No specific damages award, settlement amount, or injunctive relief disposition was disclosed in the available case record. The consolidation-based closure indicates this action was formally merged with or subordinated to a related proceeding, with the lead case’s judgment governing the resolution.

Verdict Cause Analysis

The case was filed as an infringement action, with Alnylam asserting that the defendants’ activities — specifically those relating to LNP-based RNA delivery technology embodied in the named products — infringed US11382979B2.

The presence of Alnylam’s own approved products (GIVLAARI® and OXLUMO®) among the “products involved” is procedurally notable. This listing likely reflects either: (a) Alnylam’s identification of its own products as embodying the claimed inventions to establish commercial success or nexus to the claims; or (b) a licensing or co-ownership dispute where rights to practice the patent in connection with these products were contested between the parties.

The involvement of four separate defendants — Pfizer, BioNTech SE, BioNTech Manufacturing GmbH, and Pharmacia & Upjohn — signals a deliberately broad enforcement strategy targeting multiple entities in the manufacturing and commercialization chain.

Legal Significance

The consolidation resolution, while not a trial verdict on the merits, carries important implications:

• LNP Patent Enforcement Scope: Alnylam’s willingness to assert foundational delivery patents against partners and competitors alike signals continued aggressive IP enforcement across the RNAi and mRNA therapeutic landscape.
• Multi-Defendant Strategy: Filing against multiple affiliated entities (parent companies, manufacturing subsidiaries, and commercial partners) is an increasingly common tactic to ensure complete relief and maximize settlement leverage.
• Consolidation as Resolution: The case’s consolidation into a lead matter underscores the importance of docket management and the judiciary’s efficiency-driven approach to related pharmaceutical patent disputes.

Strategic Takeaways

For Patent Holders: Assert patents broadly across the commercialization chain — manufacturers, marketers, and licensees — to preserve maximum leverage. Filing in Delaware with experienced IP counsel provides procedural predictability.

For Accused Infringers: Early evaluation of consolidation strategy can be advantageous. If parallel cases exist, coordinating across related proceedings may reduce duplicative litigation costs and enable unified claim construction positions.

For R&D Teams: Freedom-to-operate (FTO) analysis for any LNP-based RNA delivery platform must account for Alnylam’s extensive and actively enforced patent portfolio. Patent US11382979B2 and its family members represent non-trivial infringement risk for any entity formulating RNA therapeutics using lipid nanoparticle carriers.

Industry & Competitive Implications

The Alnylam v. Pfizer/BioNTech litigation reflects a broader strategic reality in the RNAi and mRNA therapeutics sector: foundational delivery technology patents are the new battleground. As LNP platforms underpin not only RNAi drugs but also mRNA vaccines and emerging gene therapies, the entities controlling core delivery patents hold extraordinary leverage over an entire class of next-generation medicines.

For Pfizer and BioNTech, whose LNP expertise gained global visibility through COVID-19 vaccine development, this litigation highlighted the IP risks embedded in commercially successful platforms. For Alnylam, patent enforcement is not merely defensive — it is a core revenue and competitive moat strategy.

The resolution by consolidation may indicate a broader cross-licensing arrangement or global settlement negotiated across multiple parallel proceedings, a trend increasingly common in high-stakes biopharma IP disputes where both parties hold commercially interdependent patent estates.

Companies in the RNAi, mRNA, and gene therapy space should monitor licensing trends emerging from Alnylam’s enforcement activity, as royalty structures and cross-license terms established in these cases will shape competitive economics across the sector for years.